Drugs for Rate Control in Atrial Fibrillation - European Society of Cardiology 2020
February 23, 2023
Approach to the management of atrial fibrillation (1)
Drugs for rate control in AF (2)
Dosage of Oral Anticoagulants (1)
Related drugs
Beta-blockers
Metoprolol
Bisoprolol
Atenolol
Esmolol
Landiolol
Nebivolol
Carvedilol
Calcium-channel blockers
Verapamil
Diltiazem
Digitalis glycosides
Digoxin
Digitoxin
Others
Amiodarone
References
Andrade JG, Aguilar M, Atzema C, et al. The 2020 Canadian Cardiovascular Society/Canadian Heart Rhythm Society Comprehensive Guidelines for the Management of Atrial Fibrillation. Can J Cardiol. 2020;36(12):1847-1948. doi:10.1016/j.cjca.2020.09.001
Canadian Journal of Cardiology (Open Access)Hindricks G, Potpara T, Dagres N, et al. 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS): The Task Force for the diagnosis and management of atrial fibrillation of the European Society of Cardiology (ESC) Developed with the special contribution of the European Heart Rhythm Association (EHRA) of the ESC [published correction appears in Eur Heart J. 2021 Feb 1;42(5):507] [published correction appears in Eur Heart J. 2021 Feb 1;42(5):546-547] [published correction appears in Eur Heart J. 2021 Oct 21;42(40):4194]. Eur Heart J. 2021;42(5):373-498. doi:10.1093/eurheartj/ehaa612
European Heart Journal (Open Access)
DISCLAIMER
⚠ This website provides general information and discussion about medications, health, and related subjects. The words and other content provided in this website, and in any linked materials, are not intended and should not be construed as medical advice. If the reader or any other person has a medical concern, he or she should consult with an appropriately-licensed physician or other legally accredited health care worker in the country that resides or is visiting.
Please do not delay your medical concerns and potential health emergencies by searching information in this website, instead look out for medical opinion in the services that exist with that specific purpose and work under the respective local health-care regulations.
The views expressed on this blog and website have no relation to those of any academic, hospital, practice or other institution with which the authors are affiliated.
For other instances, the authors of this website do not have any conflict of interest with any institution or pharmaceutical company in particular, and do not receive any compensation about any licenced drug mentioned in the website. In the same matter, the website is not intended to recommend any specific patented medication.
EMDrugs Team